NanoString Blog
Oncology
From an Egyptian Papyrus to the Hallmarks of Cancer: A Journey through the Development of Knowledge in Oncology Research
The word “cancer” was used for the first time in ancient Greece by Hippocrates, often termed the Father of Medicine for his contributions to modern medical practice. Even prior to…
Serotonin, Gut-Brain-Microbiome Axis and an Inspired Young Scientist–How a Core Facility is Born: Q&A with Prof. Beate Niesler
Imagine you are setting up for an interview with a prominent professor at the University of Heidelberg in Germany, in which you will focus on how a scientific interest triggered…
Grants Transplants
Molecular Signatures of Antibody-Mediated Rejection and Graft Outcome After Kidney Transplantation. Q&A with Dr. Dela Golshayan, M.D., Ph.D.
When Newsweek Magazine rates you the 9th best Hospital in the World, you know you are doing something remarkable! Located in Lausanne, Switzerland, Lausanne University Hospital (CHUV) sits on Lake Geneva…
Grants
Grant Writing for Dummies: Tips & Tricks for Success
Grant writing is an integral part of the life of a scientist and not an easy task. Despite multiple opportunities to obtain funding, the competition is fierce. To help our…
Digital Spatial Profiling
Excellence, Cooperation, and Passion Come Together to Serve the Scientific Community: Q&A with Dr. Peter O’Toole, University of York
Dr. Peter O’Toole, Ph.D., is the director of the Bioscience Technology Facility at the University of York in England, where he established and still leads the Imaging and Cytometry Laboratory, one of the…
Oncology
Statistically Significant Results without the Headache. Q&A with Sarah Church, Ph.D., Senior Scientist at NanoString.
Talking to Sarah, whether during social gatherings or within the office walls, is always a pleasure. Dr. Church is a Senior Scientist at NanoString and one of the warmest people…
Immunology Infectious Disease
COVID-19 Pathogenesis Steps Out of the Shadows
“Analysis of pulmonary vessels showed that widespread thrombosis with microangiopathy ─ a severe condition wherein small blood clots are formed within the tiniest of blood vessels ─ was 9x more…
Spotlight on a CRO: Interview with the Team of Scientists behind NeoGenomics Pharma Services
NeoGenomics is a cancer diagnostics and pharma services company serving pharmaceutical companies and academic centers. They specialize in diagnostic, prognostic and predictive testing using the most innovative technologies. The company…
Oncology
Going Beyond PDL-1. Q&A with Dr. Nina Radosevic- Robin, MD.
Dr. Nina Radosevic-Robin, MD, is a Board-Certified Surgical/Molecular Pathologist at Centre Jean Perrin, a Sr. Scientist within the Unit 1240 of French National Institute for Medical Research (INSERM), and a…
Immunology Oncology
Why is Spatial Transcriptomics Critical to Studying Sarcomas? Q&A with Dr. Troy McEachron, Ph.D
“Whereas the EWS specimens tended to have very simple genomes, the osteosarcoma specimens looked like a hand grenade had gone off in the genome. These were the most fragmented and…
Grants Transplants
Solid Organ Transplantation and the Immunology of Rejection. Q&A with GeoMx® Digital Spatial Profiler Grant Winner Dr. Fadi Issa
“Cancer immunotherapy and transplantation are basically the same field; one’s just the flip side of the other”. Dr. Fadi Issa Have you ever been to Oxford? Situated in the gorgeous…
Grants Transplants
Searching for New Biomarkers to Prevent Organ Transplant Rejection. Q&A with HOT Panel Grant Winner Dr. Evan Farkash
Bob’s first question to me was: “How much do you want to learn about kidney pathology?” My response was that I wanted to learn as much as I could, and…